Shuttle Pharma Expands Patent Coverage On HDAC Inhibitor Platform
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharma is expanding its patent coverage on its HDAC inhibitor platform. The platform includes pre-clinical inhibitors SP-2-225, SP-1-161, and SP-1-303, each with unique properties and potential applications in cancer treatment. The company is advancing drug manufacture and IND-enabling studies with the goal of enabling a Phase I clinical trial in 2024.
September 11, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharma's expansion of its patent coverage on its HDAC inhibitor platform could potentially lead to advancements in cancer treatment. This could positively impact the company's stock in the short term.
The expansion of patent coverage on Shuttle Pharma's HDAC inhibitor platform indicates progress in the company's research and development efforts. This could potentially lead to advancements in cancer treatment, which could increase the company's value and positively impact its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100